Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy Volunteers

Pfizer

Status and phase: Completed; Phase 1

Conditions: Rheumatoid Arthritis

Treatments: Drug: Metformin/CP-690,550

Study type: Interventional

Funder types: Industry

Identifiers

NCT01405118

A3921143

Details and patient eligibility

About

This study will evaluate the potential effect of CP 690,550 on the pharmacokinetics of metformin, a probe drug for organic cationic transport.

Enrollment: 24 estimated patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Adult healthy male and/or female (of non child bearing potential) subjects.

Exclusion criteria

• Subjects with clinically significant systemic and laboratory abnormalities.
• Subjects with clinically significant infections within the past 3 months.
• Women of child-bearing potential.

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

24 participants in 1 patient group

Metformin/CP-690,550

Experimental group

Treatment:

Drug: Metformin/CP-690,550